CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

FDA accepts Biohaven's Vyglxia resubmission for review in spinocerebellar ataxia

By Public Technologies
  • Biohaven announced Oct. 22, 2026, that the FDA accepted its Vyglxia (troriluzole) application resubmission for review in spinocerebellar ataxia.
  • The resubmission included new positive supportive analyses already submitted to the FDA.
  • The agency deemed the resubmission a complete response to its Nov. 4, 2025, action letter.
  • The FDA set a user fee goal date in the first quarter of 2027.
  • The Peripheral and Central Nervous System Advisory Committee will review the application; its meeting date will be announced soon.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001935979-26-000083), on October 22, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk